Advertisement

Current Advances in BMT for Cancer Treatment

  • Dahlia V. Kirkpatrick
  • Lilian Delmonte
Part of the Cancer Growth and Progression book series (CAGP, volume 10)

Abstract

Bone marrow transplantation (BMT) has become an accepted form of treatment for acute leukemia, aplastic anemia, and severe combined immunodeficiencies, and has recently become an alternative treatment for solid tumors, particularly lymphoma. The purpose of BMT is to repopulate the hemopoietic and lymphoid system following eradication of malignant cells with extremely high doses of chemotherapy (CT) and/or radiotherapy (RT) and, hopefully, to inhibit progression of the malignant process.

Keywords

Acute Lymphoblastic Leukemia Bone Marrow Transplantation Autologous Bone Marrow Allogeneic Bone Marrow Transplantation Hairy Cell Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations

AL

acute leukemia

ALL

acute lymphoblastic leukemia

ANLL

acute non-lymphocytic leukemia

AP

acute phase

ASTA-Z

mephosphamide

BCNU

carmustine

BMT

bone marrow transplantation

BP

blast phase (blast crisis)

CGL

chronic granulocytic leukemia (see CML)

CML

chronic myelocytic leukemia (see CGL)

CP

chronic phase

CP-1

first chronic phase

CP-2

second chronic phase

CR

complete response: 100% regression of all measurable lesions

CR-1

first complete remission

CR-2

second complete remission

CR-3

third remissions

CT

chemotherapy

DMSO

dimethyl sodium dioxide

DTIC

dacarbazine

EBV

Epstein-Barr virus

4-HC

4-hydroperoxycyclophosphamide

GvHD

graft-versus-host disease

GvL

graft-versus-leukemia

HCL

hairy cell leukemia

HD

Hodgkin’s disease

MAb

monoclonal antibody

NHL

non-Hodgkin’s lymphoma

PR

parital response: ≥50% regression of all measurable marrow

RT

radiotherapy

SBA

soybean hemagglutinin

SCLC

small cell lung carcinoma (oat cell carcinoma)

TBI

total body irradiation

VP-16

etoposide

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Appelbaum FR, Deiseroth AB, Graw RG, et al.: Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer 41:1059, 1978PubMedCrossRefGoogle Scholar
  2. 2.
    Appelbaum FR, Herzig G, Graw RG, et al.: Accelerated hemopoietic recovery following the infusion of cyropreserved autologous bone marrow in human. Exp Hematol 7 (Suppl 5):297, 1979PubMedGoogle Scholar
  3. 3.
    Appelbaum FR, Dahlberg S, Thomas ED, et al.: Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Int Med 101:581, 1984PubMedGoogle Scholar
  4. 4.
    August C, Elkins W, Evans A, et al.: Metastatic neuroblastoma (M/NBL) managed by supralethal therapy and bone marrow reconstitution (BMRC). Results of a four-institution Children’s Cancer Study Group pilot study. Proc 3rd Conf Adv Neuroblastoma Res May, 1984 (abstr)Google Scholar
  5. 5.
    August C, Serota FT, Koch PA, et al.: Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation and allogeneic or autologous marrow reconstitution. J Clin Oncol 2:609, 1984 (abstr)PubMedGoogle Scholar
  6. 6.
    August CS, Elkins WL, Burkey E, et al.: Treatment of advanced metastatic neuroblastoma with supralethal chemotherapy. In: Autologous Bone Marrow Transplantation, pp. 167–171. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute at Houston, 1985Google Scholar
  7. 7.
    Barnes DWA, Corp MJ, Loutit JE, Neal FE: Treatment of murine leukemia with x-rays and homologous bone marrow. BR Med J,626, 1956Google Scholar
  8. 8.
    Bast RC Jr, Di Fabritiis P, Mayer C, et al.: Application of monoclonal antibodies to autologous bone marrow transplantation. 13th Int Congr Chemother, Vienna. SS76, 1983Google Scholar
  9. 9.
    Bast RC Jr, Sallan SE, Reynolds C, et al.: Autologous bone marrow transplantation for CALLA-positive acute lymphoblastic leukemia: An update. In: Autologous Bone Marrow Transplantation,pp. 3–6. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute at Houston, 1985Google Scholar
  10. 10.
    Baugham ASJ, Worsley AM, McCarthy DM, et al.: Hematological reconstitution and severity of graft versus host disease after bone marrow transplant for chronic granulocytic leukemia: The influence of previous splenectomy. Brit J Haematol 56:445, 1984CrossRefGoogle Scholar
  11. 11.
    Bernard JL, Philip T, Zucker JM, et al.: 91 successive BMT in advanced neuroblastoma. ASCO/AACR 24th Ann Meetg Prog, 1988Google Scholar
  12. 12.
    Biron P, Philip T, Maraninchi D, et al.: Massic chemotherapy and autologous bone marrow transplantation to progressive disease of nonseminomatous testicular cancer. In: Proc 1st Conf on Autologous Bone Marrow Transplantation, pp. 203–210. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute at Houston, 1985Google Scholar
  13. 13.
    Blume K, Beutler E, Bross KJ, et al.: Bone marrow ablation and allogeneic marrow transplantation in acute leukemia. New Engl J Med 302:1041, 1980PubMedCrossRefGoogle Scholar
  14. 14.
    Bortin MM, Truit RL, Rimm A. Graft versus leukemia reactivity induced by alloimmunization without augmentation of graft versus host reactivity. Nature 281:490, 1979PubMedCrossRefGoogle Scholar
  15. 15.
    Brenner MK, Grob JP, Prentice HG: The use of monoclonal antibodies in graft versus host disease prevention. Haematologia (Budap) 19(3):167, 1986Google Scholar
  16. 16.
    Brun del Re G, Baumgartner C, Bleher EA, et al.: Autologous bone marrow transplantation in the treatment of advanced malignant tumors in children and adolescents. Folia Haematol (Leipzig) 111:243, 1984Google Scholar
  17. 17.
    Buckner CD, Clift RA, Fefer A, et al.: Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 2:138, 1974PubMedGoogle Scholar
  18. 18.
    Buckner JC, Stewart P, Clift RA, et al.: Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation, and infusion of cryopreserved autologous marrow. Exp Hematol 6:96, 1978PubMedGoogle Scholar
  19. 19.
    Burnett AK: Prolonged survival in patients with acute myeloid leukemia in first remission following autologous bone marrow transplantation. In: Proc 1st Conf on Autologous Bone Marrow Transplantation,pp. 7–10. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  20. 20.
    Butturini A, Rivera GK, Bortin JJ, Gale RP: Which treatment for childhood acute lymphoblastic leukaemia in second remission? Lancet Feb 21; 1(8530):429, 1987PubMedCrossRefGoogle Scholar
  21. 21.
    Champlin R, Ho W, Arenson E, et al.: Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Blood 60:1038, 1982PubMedGoogle Scholar
  22. 22.
    Champlin RE, Ho WG, Gale RP, et al.: Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med 102:285, 1985PubMedGoogle Scholar
  23. 23.
    Cheever MA, Fefer A, Greenberg PD, et al.: Treatment of hairy cell leukemia with chemoradiotherapy and identical twin bone marrow transplantation. New Engl J Med 307:479, 1982PubMedCrossRefGoogle Scholar
  24. 24.
    Collins SJ, Ruscetti FK, Gallagher RE, et al.: Terminal differentiation of promyelocytic leukemic cell induced by diemthyl-sulfoxide and other polar compounds. Proc Natl Acad Sci USA 75:2458, 1978PubMedCrossRefGoogle Scholar
  25. 25.
    Cornbleet MA, Corringham REJ, Prentice HG, et al.: Treatment of Ewing’s sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 65:241, 1981PubMedGoogle Scholar
  26. 26.
    Cunningham I, Gee T, Dowling M, et al.: Results of treatment of Ph + chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53:375, 1979PubMedGoogle Scholar
  27. 27.
    Deeg HJ, Prentice R, Fritz TE, et al.: Increased incidence of malignant tumors in dogs after total body irradiation and marrow transplantation. Int J Radiat Oncol Biol Phys 9:1505, 1983PubMedGoogle Scholar
  28. 28.
    Deeg HJ, Sanders J, Martin P, et al.: Secondary malignancies after marrow transplantation. Exp Hematol 12:660, 1984PubMedGoogle Scholar
  29. 29.
    DeVita V, Canellos G, Hubbard S, et al.: Chemotherapy of Hodgkin’s disease (HD) with MOPP: A 10 year progress report. Proc Am Soc Clin Oncol 17:269, 1976 (abstr)Google Scholar
  30. 30.
    Dinsmore R, Kirkpatrick D, Flomenberg N, et al.: Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia. Blood 62:381, 1983PubMedGoogle Scholar
  31. 31.
    Dinsmore R, Kirkpatrick D, Flomenberg N, et al.: Allogeneic bone marrow transplantation for patients with acute non-lymphocytic leukemia. Blood 63:649, 1984PubMedGoogle Scholar
  32. 32.
    Douay FK, Gorin NC, Najman A, et al.: Continuous bone marrow culture: Sensitivity to chemotherapeutic agents of probable pluripotential stem cells. Application to autologous bone marrow transplantation. Exp Hematol 11 (Suppl 14):7, 1983 (abstr)Google Scholar
  33. 33.
    Douer D, Champlin RE, Ho WG, et al.: High dose combination therapy and autologous bone marrow transplantation in resistant cancer. Am J Med 71:973,1981PubMedCrossRefGoogle Scholar
  34. 34.
    Ekert H, Ellis WM, Waters KD, et al.: Autologous bone marrow rescue in the treatment of advanced tumors of childhood. Cancer 49:603, 1982PubMedCrossRefGoogle Scholar
  35. 35.
    Fabian I, Douer D, Wells JR, et al.: Cryopreservation of the human stem cell. Exp Hematol 10:119, 1982PubMedGoogle Scholar
  36. 36.
    Fay JW, Levine NM, Phillips GL, et al.: Treatment of metastatic melanoma with intensive l,3-BIS(2-chloroethyl)-1nitrosourea (BCNU) and autologous marrow transplantation (AMX). Proc Am Assoc Cancer Res 22:532, 1981 (abstr)Google Scholar
  37. 37.
    Fay JW, Phillips GL, Herzig GP, et al.: Treatment of refractory malignant lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Exp Hematol 11(5):406, 1985 (abstr)Google Scholar
  38. 38.
    Fefer A, Cheever MA, Thomas ED, et al.: Disappearance of Ph’-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation form an identical twin. New Engl J Med 300:333, 1974CrossRefGoogle Scholar
  39. 39.
    Fefer A, Cheever MA, Greenberg PD, et al.: Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. New Engl J Med 306:63, 1982PubMedCrossRefGoogle Scholar
  40. 40.
    Fefer A, Greenberg PD, Cheever MA, et al.: Treatment of multiple myeloma (MM) with chemoradiotherapy and identical twin bone marrow transplantation (BMT). Proc Am Sco Clin Oncol 1:C-731, 1982 (abstr)Google Scholar
  41. 41.
    Fefer A, Cheever MA, Greenberg PD, et al.: Bone marrow transplantation (BMT) for acute leukemia in patients with identical twins: improved results with BMT in complete remission (CR). Proc Annu Meet Am Soc Clin Oncol 2:C-708, 1983 (abstr)Google Scholar
  42. 42.
    Filipovich AH: Progress in broadening the uses of marrow transplantation: donor availability. Vox Sang 51 Suppl 2:95, 1986PubMedCrossRefGoogle Scholar
  43. 43.
    Forman SF, Spruce WF, Farbstein MJ, et al.: Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood 61:439, 1983PubMedGoogle Scholar
  44. 44.
    Gale RP, Kay Humphrey, Rimm A, Bortin M: Bone marrow transplantation for Acute Leukemia in first remission. Lancet 8:10, 1982Google Scholar
  45. 45.
    Gale RP, Champlin RE: How does bone marrow transplantation cure leukemia? Lancet 7:28, 1984CrossRefGoogle Scholar
  46. 46.
    Gee AP, Graham-Pole J, Boyle MDP: Purging bone marrow for autologous transplantation - Are methods for monitoring the elimination of tumor cells reliable? Exp Hematol 11 (Suppl 14):7, 1983 (abstr)Google Scholar
  47. 47.
    Goldman JM, for the Advisory Committee of the International Bone Marrow Transplant Registry. Blood 66 (Suppl 1):251a, 1985 (abstr)Google Scholar
  48. 48.
    Goldman JM, Baugham A: Application of bone marrow transplantation in chronic granulocytic leukemia. Clin Hematol 12:739, 1983Google Scholar
  49. 49.
    Goldman JM, Catovsky D, Galton DAG: Reversal of blast-cell crisis in CGL by transfusion of stored autologous buffycold cells. Lancet 1:437, 1978PubMedCrossRefGoogle Scholar
  50. 50.
    Goldman JM, Johnson SA, Catovsky D, et al.: Identical twin marrow transplantation for patients with leukemia and lymphoma. Transplantation 31:140, 1981PubMedCrossRefGoogle Scholar
  51. 51.
    Goldman JM, Catovsky D, Goolden AWG, et al.: Buffy coat autografts for patients with chronic granulocytic leukaemia in transformation. Blut 42:149, 1982CrossRefGoogle Scholar
  52. 52.
    Goldstone AH: Autologous bone marrow transplantation for non-Hodgkin’s lymphoma: The preliminary European experience. In: Proc Ist Internatl Symp on Autologous Bone Marrow Transplantation, pp. 67–74. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  53. 53.
    Golomb HM, Schmidt K, Iman JW: Chlorambucil therapy of twenty-four post-splenectomy patients with progressive hairy cell leukemia. Sem Oncol 11:502, 1984Google Scholar
  54. 54.
    Gorin NC, Najman A, Salmon C, et al.: High dose combination chemotherapy (TACC) with and without autologous bone marrow transplantation for the treatment of acute leukaemia and other malignant diseases. Eur J Cancer 15:1113, 1979PubMedCrossRefGoogle Scholar
  55. 55.
    Gorin NC, Najman A, Van der Akker J, et al.: Disappearance of Philadelphia chromosome after autologous bone marrow transplantation for treatment of chronic myeloid leukaemia in acute crisis. Lancet 1(8262):44, 1982 (Letter)PubMedCrossRefGoogle Scholar
  56. 56.
    Gorin NC, Duay FK, Jansen GA, et al.: Preclinical study of immunotoxin T101: Absence of cytotoxicity against hemopoietic progenitor stem cells. Application to in vitro therapy prior to autologous bone marrow transplantation. Exp Hematol 11 (Suppl 14):6, 1983 (abstr)Google Scholar
  57. 57.
    Graham-Pole J: Transplantation for patients with neuroblastoma. Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation,pp. 173–182. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  58. 58.
    Graham-Pole J, Lazarus HM, Herzig RH, et al.: High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing’s sarcoma. Am J Pediatr Hematol Oncol 6:17, 1984PubMedGoogle Scholar
  59. 59.
    Gulati SC, Helson L, Langleben A, et al.: Therapy of disseminated neuroblastoma with intensive therapy and autologous stem cell rescue. SLOP 14:25, 1982 (abstr)Google Scholar
  60. 60.
    Gulati SC, Fedorciw B, Gopal A, et al.: Autologous stem cell transplant for poor prognosis diffuse histiocytic lymphoma. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation,pp. 75–81. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  61. 61.
    Gulati S, Helson L, et al.: Presented orally at the International Autologous Transplant Meeting, Parma, Italy, 1985Google Scholar
  62. 62.
    Harper PG, Souhami RL, Spiro SG, et al.: A review of the use of very high dose chemotherapy in small cell carcinoma of the lung. Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 141–148. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor:Institute, Houston, Texas, 1985Google Scholar
  63. 63.
    Harris R, Feig S, Coccia P, et al.: All in second remission - A CCSG study of maintenance chemotherapy vs marrow transplantation. In: Progress in Bone Marrow Transplantation,pp. 91–92. Alan R Liss, New York, 1987Google Scholar
  64. 64.
    Hartmann O, Kalifa C, Bayle C, et al.: Treatment of stage IV neuroblastoma with high-dose chemotherapy regimens and autologous bone marrow transplantation. Proc Third Conf Adv Neuroblastoma Res,1984 (abstr)Google Scholar
  65. 65.
    Hartmann O, Kalifa C, Benhamou E, Patte C, Flamant F, Jullien C, Beaujean F, Lemerle J: Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 16(2):165, 1986PubMedCrossRefGoogle Scholar
  66. 66.
    Hassett JM, Zaroulis CG, Greenberg ML, Siegal FP: Bone-marrow transplantation in AIDS. N Engl J Med 1983; 309:11–665Google Scholar
  67. 67.
    Helson L, Gulati S, O’Reilly R, et al.: Autologous bone marrow transplantation (ABMT) in neuroblastoma (NBL). Proc Third Conf Adv Neuroblastoma Res,1984 (abstr)Google Scholar
  68. 68..
    Herzig RH, Phillips GL, Lazarus HM, et al.: Intensive chemotherapy and autologous bone marrow transplantation for the treatment of refractory malignancies. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 197–202. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  69. 69.
    Hill RS, Buskard NA, Still BJ, et al.: Studies of cryopreservative methods for human bone marrow. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation,pp. 273–279. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  70. 70.
    Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin’s lymphoma. N Engl J Med 311:1471, 1984PubMedCrossRefGoogle Scholar
  71. 71.
    Ihre DC, Lichter AS, Deisseroth AB, et al.: Late intensive combined modality therapy with autologous bone marrow infusion in extensive stage small cell lung cancer. Proc Am Assoc Clin Oncol 2:198, 1983 (abstr C-774)Google Scholar
  72. 72.
    Jacobs AD, Champlin RE, Golde DW: Recombinant alpha2-interferon for hairy cell leukemia. Blood 65:1017, 1985PubMedGoogle Scholar
  73. 73.
    Jagannath S, Dicke KA, Spitzer G, et al.: Role of autologous transplantation in Hodgkin’s disease. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation,pp. 83–86. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  74. 74.
    Jansen FK, Blythman HE, Carriere D, et al.: Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunologic Rev 62:185, 1982CrossRefGoogle Scholar
  75. 75.
    Johnson FL, Thomas ED, Clark BS, et al.: A comparison of marrow transplantation to chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. New Engl J Med 305:846, 1981PubMedCrossRefGoogle Scholar
  76. 76.
    Kaizer H, Stuart RK, Colvin M, et al.: Autologous bone marrow transplantation in acute leukemia: A pilot study utilizing in vitro incubation of autologous marrow with 4hydroperoxycyclophosphamide (4HC) prior to cryopreservation. Proc Am Soc Clin Oncol 22:483, 1981 (abstr)Google Scholar
  77. 77.
    Kemshead JT, Ugelstad J, Rembaum A, et al.: Monoclonal antibodies attached to microspheres containing magnetic compounds, used to remove neuroblastoma cells from bone marrow taken for autologous transplantation. Proc XIVth Mett Internatl Soc Ped Oncol,Bern, Switzerland, 1982, P-14Google Scholar
  78. 78.
    Kersey JH, Ramsay NKC, Kim T, et al.: Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: A pilot study. Blood 60:400, 1982PubMedGoogle Scholar
  79. 79.
    Knight WA III: Autologous bone marrow transplantation for human solid tumors. Tex Med 80:50, 1984PubMedGoogle Scholar
  80. 80.
    Kolb HJ, Ledderose R, Hartenstein B, et al.: Autologous bone marrow transplantation in patients with advances teratocarcinoma. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation,pp. 211–217. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  81. 81.
    Koller C, Miller D: Preliminary observations on the therapy of myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. NE Journal of Medicine 315:23, 1986Google Scholar
  82. 82.
    Korbling M, Burke P, Braine H, et al.: Successful engraft-ment of blood-derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 9:684, 1981PubMedGoogle Scholar
  83. 83.
    Lanzkowsky P (ed): Pediatric Oncology. McGraw-Hill Book Co, New York, 576 pp., 1982Google Scholar
  84. 84.
    Laure F, Rouvioux C, et al.: Reduction of HIV-1 DNA in infants and children by means of the polymerase chain reaction. Lancet 2: 538–541, 1988PubMedCrossRefGoogle Scholar
  85. 85.
    Lister TA, Ronatiner AZS: The treatment of acute myelogenous leukemia in adults. Sem Hematol 19:172, 1982Google Scholar
  86. 86.
    McElwain JJ, Hedley DW, Burton G, et al.: Marrow auto-transplantation accelerated haematological recovery in patients with malignant melanoma treated with high dose melphalan. Brit J Cancer 40:72, 1979PubMedCrossRefGoogle Scholar
  87. 87.
    McGlave PB, Kim TH, Hurd DD, et al.: Successful allogeneic bone marrow transplantation for patients in the accelerated phase of chronic granulocytic leukemia. Lancet 2(8299):625, 1982PubMedCrossRefGoogle Scholar
  88. 88.
    Mage M, Gee TS, Arlin Z, et al.: Androgen therapy in post-splenectomy patients with hairy cell leukemia. Blood 58 (Suppl 1):145a, 1981 (abstr)Google Scholar
  89. 89.
    Martin PJ, Shulman HM, Schubach WH, et al.: Fatal Epstein-Barr virus associated proliferation of donor B cells after treatment of acute graft versus host disease with a murine anti-T cell antibody. Ann Int Med 10:310, 1984Google Scholar
  90. 90.
    Mathe G, Amiel JL, Schwarzenberg L: Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 25:1525, 1965PubMedGoogle Scholar
  91. 91.
    Miller DR: Acute lymphoblastic leukemia. Ped Clin North America 27:269, 1980Google Scholar
  92. 92.
    Miller RA, Levy R: Response of cutaneous T-cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2:226, 1981PubMedCrossRefGoogle Scholar
  93. 93.
    Miller RA, Maloney DG, Warnke R, et al.: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med 306:517, 1982CrossRefGoogle Scholar
  94. 94.
    Minna JD, Higgins GA, Glatstein EJ: In: Cancer: Principles and Practice of Oncology, pp. 396–474. Edited by V de Vita Jr, S Hellman, S Rosenberg. JB Lippincott, Philadelphia, 1983Google Scholar
  95. 95.
    Nadler LM, Takavorian T, Botnick L, et al.: Anti-B 1 monoclonal antibody and complement in treatment of autologous bone marrow transplantation for relapsed B-cell non-Hodgkin’s lymphoma. Lancet 2(8400): 427, 1984PubMedCrossRefGoogle Scholar
  96. 96.
    Netzel B, Rodt H, Haas RJ, et al: Immunologic conditioning of bone marrow for autotransplantation in childhood acute lymphoblastic leukemia. Lancet 2: 1330, 1980CrossRefGoogle Scholar
  97. 97.
    Nkrumah FK, Perkins I: Burkitt’s lymphoma in Ghana: Clinical features and response to chemotherapy. Int J Cancer 17: 445, 1976CrossRefGoogle Scholar
  98. 98.
    O’Leary M, Ramsay NK, Nesbit ME Jr, et al.: Bone marrow transplantation for non-Hodgkin’s lymphoma in children and young adults. A pilot study. Am J Med 74: 497, 1983PubMedCrossRefGoogle Scholar
  99. 99.
    Osserman EF, DiRe LB, Sherman WH, et al.: Identical twin marrow transplantation in multiple myeloma. Acta Haematol (Basel) 68(3): 215, 1982CrossRefGoogle Scholar
  100. 100.
    Owens AH Jr: Effect of graft versus host disease on the course of L1210 leukemia. Exp Hematol 20: 43, 1970Google Scholar
  101. 101.
    Ozer H, Han T, Nussbaum-Blumenson A, et al.: Allogeneic bone marrow transplantation and idiotype (ID) monitoring in multiple myeloma. Proc Am Soc Ca Res 25: 161, 1984 (abstr)Google Scholar
  102. 102.
    Papa G, Arcese W, Mauro FR, Bianchi A, Alimena G, DeFelice L, Isacchi G, Pasqualetti D, Malagnino F, Purpura M, et al.: Standard conditioning regimen and T-depleted donor bone marrow for transplantation in chronic myeloid leukemia. Leuk Res 10(2): 1469, 1986PubMedCrossRefGoogle Scholar
  103. 103.
    Peters WP: Autologous bone marrow support in treating breast cancer: In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 189–195. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  104. 104.
    Philip T, Biron P, Maraninchi D, et al.: Massive chemotherapy with autologous bone marrow transplantation in 50 cases of non-Hodgkin’s lymphoma with poor prognosis. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 89–107. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  105. 105.
    Philip T, Biron P, Philip M, et al.: Burkitt’s lymphoma and autologous bone marrow transplantation: An overview. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 109–115. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  106. 106.
    Philip T, Bernard JL, Zucker JM, Pinkerton R, Lutz P, Bordigoni P, Plouvier E, Robert A, Carton R, Philippe N, et al.: High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma; an unselected group of stage IV patients over 1 year of age. J Clin Oncol Feb 5(2): 266, 1987Google Scholar
  107. 107.
    Phillips GL: Current clinical trials with intensive therapy and autologous bone marrow. In: Recent Advances in Bone Marrow Transplantation, pp. 567–597. Edited by RP Gale. Alan R Liss, Inc, New York, 1983Google Scholar
  108. 108.
    Phillips GL, Herzig RH, Lazarus HM, et al.: Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation and transplantation of cryopreserved autologous marrow. New Engl J Med 310:1557, 1984PubMedCrossRefGoogle Scholar
  109. 109.
    Portlock CS, Rosenberg SA: Chemotherapy of the non-Hodgkin’s lymphomas. The Stanford experience. Cancer Treat Rep 61: 1049, 1977PubMedGoogle Scholar
  110. 110.
    Portlock CS, Rosenberg SA: No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 90: 10, 1979PubMedGoogle Scholar
  111. 111.
    Powles RL, Morgenstern G, Clink HM, et al.: The place of bone marrow transplantation in acute myelogenous leukemia. Lancet 1: 1047, 1980PubMedCrossRefGoogle Scholar
  112. 112.
    Powles RL, Palu G, Raghavan D: The curability of acute leukemia. In: Topical Reviews in Haematology, pp. 186–219. Edited by S Roath. London, John Wright, 1980Google Scholar
  113. 113.
    Pritchard J, McElwain TJ, Graham-Pole J: High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Brit J Cancer 45: 86, 1982PubMedCrossRefGoogle Scholar
  114. 114.
    Quesada JR, Reuben JR, Manning JT, et al.: Alpha interferon for the induction of remission in hairy cell leukemia. N Engl J Med 310: 15, 1984PubMedCrossRefGoogle Scholar
  115. 115.
    Ramsay N, LeBien T, Nesbit M, et al.: Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: Results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. Blood 66: 508, 1985PubMedGoogle Scholar
  116. 116.
    Ratain MJ, Golomb HM, Vardiman JW, et al.: Treatment of hairy cell leukemia with recombinant alpha-2 interferon. Blood 65: 644, 1985PubMedGoogle Scholar
  117. 117.
    Reece DE, Buskard NA, Hill RS, Fryer CJ, Naiman SC, Phillips GL: Allogeneic bone marrow transplantation for Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Res 10(4): 457, 1986PubMedCrossRefGoogle Scholar
  118. 118.
    Reiffers J, Vezon G, Bernard P, et al.: Hemopoietic stem cell autografting for chronic granulocytic leukemia in transformation. Exp Hematol 11 (Suppl 13): 148, 1983Google Scholar
  119. 119.
    Ritz J: Use of monoclonal antibodies in autologous and allogeneic bone marrow transplantation. Clin Hematol 12: 813, 1983Google Scholar
  120. 120.
    Ritz J, Bast RC, Clavell LA, et al.: Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukaemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 2: 60, 1982PubMedCrossRefGoogle Scholar
  121. 121.
    Rizzoli V, Caramatti C, Mangoni L: The effect of 4-hydroperoxycyclophosphamide (4HC) and VP-16–213 on leukemic and normal myeloid progenitor cells. Exp Hematol 11 (Suppl 14): 9, 1983 (abstr)Google Scholar
  122. 122.
    Rosenberg SA: The low-grade non-Hodgkin’s lymphomas: Challenges and opportunities. J Clin Oncol 3: 299, 1985PubMedGoogle Scholar
  123. 123.
    Rowley SD, Stuart RK: 4-hydroperoxycyclophosphamide (4-HC) effects on human pluripotent stem cells (CFUGEMM) in vitro. Exp Hematol 11 (Suppl 14): 8, 1983 (abstr)Google Scholar
  124. 124.
    Sanders JE, Thomas ED, the Seattle Marrow Transplant Group: Marrow transplantation for children with acute nonlymphoblastic leukemia in first remission. Blood 66: 460, 1985PubMedGoogle Scholar
  125. 125.
    Sanders JE, Thomas ED: Marrow transplantation for children with acute nonlymphoblastic leukemia in first remission. Med Pediatr Oncol 9(5): 423, 1981PubMedCrossRefGoogle Scholar
  126. 126.
    Schubach WH, Hackman R, Neiman PE, et al.: A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood 60: 180, 1982PubMedGoogle Scholar
  127. 127.
    Schubach WH, Miller G, Thomas ED: Epstein-Barr virus genomes are restricted to secondary neoplastic cells following bone marrow transplantation. Blood 65: 535, 1985PubMedGoogle Scholar
  128. 128.
    Scott EP, Forman SJ, Spruce WE, et al.: Bone marrow ablation followed by allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia during complete remission. Transplant Proc 15: 1395, 1983Google Scholar
  129. 129.
    Siena S, Castro-Malaspina H, Gulati SC, et al.: Effect of in vitro purging with 4-hydroperoxycyclophosphamide (4-HC) on the hemopoietic microenviromental elements of human bone marrow. Blood 65: 655, 1985PubMedGoogle Scholar
  130. 130.
    Speck B, Bortin MM, Champlin R, et al.: Allogeneic bone-marrow transplantation for chronic myelogenous leukemia. Lancet 1(8378): 665, 1984PubMedCrossRefGoogle Scholar
  131. 131.
    Spiegel Robert J: Intron A (Interferon Alfa-26): Clinical Overview and Future Directions. Seminars in Oncology 13: 3 Suppl 2, 1986Google Scholar
  132. 132.
    Spiers ASD, Parekh SJ, Bishop MB: Hairy cell leukemia: Induction of complete remission with pentostatin (2’-deoxycoformycin). J Clin Oncol 2: 1336, 1984PubMedGoogle Scholar
  133. 133.
    Spitzer G, Valdivieso M, Farha P, et al.: Bone marrow support in limited small cell bronchogenic carcinoma. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 155–160. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  134. 134.
    Stewart P, Sanders J: Marrow transplantation for acute lymphoblastic leukemia in first remission. Proc 13th Internatl Cancer Congr, Seattle, UICC, Abstr 794, 1982Google Scholar
  135. 135.
    Syman M, Humblet Y, Bosly A, et al.: Treatment of small cell lung cancer with non-cross-resistant induction and intensive consolidation chemotherapy and autologous marrow transplantation: A randomized study. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 161–165. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  136. 136.
    Tannir N, Spitzer G, Dicke K, et al.: Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep 68: 805, 1984PubMedGoogle Scholar
  137. 137.
    Thomas ED, Buckner CD, Banaji M, et al.: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic bone marrow transplantation. Blood 49: 511, 1977PubMedGoogle Scholar
  138. 138.
    Thomas ED, Buckner CD, Clift RA, et al.: Marrow transplantation for acute nonlymphoblastic leukemia in first remission. New Engl J Med 301: 597, 1979PubMedCrossRefGoogle Scholar
  139. 139.
    Thomas ED, Sanders JE, Flournoy N, et al.: Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 54: 468, 1979PubMedGoogle Scholar
  140. 140.
    Thomas ED: Marrow transplantation for marrow failure or leukemia. Compr Ther 6(7): 69, 1980PubMedGoogle Scholar
  141. 141.
    Thomas ED, Clift RA, Buckner CD: Marrow transplantation for patients with acute nonlymphoblastic leukemia who achieve first remission. Cancer Treat Rep 66: 1463, 1982PubMedGoogle Scholar
  142. 142.
    Thomas ED, Sanders JE, Flournoy N, et al.: Marrow transplantation for patients with acute lymphoblastic leukemia: A long-term follow-up. Blood 62: 1139, 1983PubMedGoogle Scholar
  143. 143.
    Treleaven JG, Gibson FM, Uglestad J, et al.: Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1: 70, 1984PubMedCrossRefGoogle Scholar
  144. 144.
    Uckun FM, Azemove SM, Myers DE, Vallera DA: AntiCO2 (T, p50) intact ricin immunotoxins for GVHD-prophylaxis in allogeneic bone marrow transplantation. Leuk Res 10(2): 145, 1986PubMedCrossRefGoogle Scholar
  145. 145.
    Weiden PL, Flournoy M, Thomas ED, et al.: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. New Engl J Med 300: 1068, 1979PubMedCrossRefGoogle Scholar
  146. 146.
    Wells JE, Billing R, Herzig R, et al.: Autotransplantation after in vitro immunotherapy of lymphoblastic leukemia. Exp Hematol 7: 164, 1979PubMedGoogle Scholar
  147. 147.
    Williams SF, Bitran JD, Kaminer L, Westbrook C, Jacobs R, Ashenhurst J, Robin E, Purl S, Beschorner J, Schroeder C, et al.: A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol Feb 5(2): 260, 1987PubMedGoogle Scholar
  148. 148.
    Wolf NS, Phillips GL, Fay JW, et al.: Transplantation for primary tumors of the central nervous system: Phase II and III studies of the Southeastern Cancer Study Group. In: Proc 1st Internatl Symp on Autologous Bone Marrow Transplantation, pp. 255–259. Edited by KA Dicke, G Spitzer, AR Zander. UT MD Anderson Hospital and Tumor Institute, Houston, Texas, 1985Google Scholar
  149. 149.
    Wolff SN, Phillips GL, Herzig GP: High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system. Cancer Treat Rep 71(2): 183, 1987PubMedGoogle Scholar
  150. 150.
    Woods WG, Nesbit NE, Ramsay NKC, et al.: Intensive therapy followed by bone marrow transplantation for patients with acute lymphocytic leukemia in second or subsequent remission. Determination of prognostic factors (a report from the University of Minnesota bone marrow transplant team). Blood 6: 1182, 1983Google Scholar
  151. 151.
    Woods WG: Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Prevention of graft-vs. host disease. Am J Pediatr Hematol Oncol 6(3): 283, 1984PubMedCrossRefGoogle Scholar
  152. 152.
    Yam LT, Klick JC, Mielke CH: Therapeutic leukapheresis in hairy cell leukemia: Review of literature and personal experience. Sem Oncol 11: 493, 1984Google Scholar
  153. 153.
    Ziegler JL: Burkitt’s lymphoma. Med Clin No Amer 61: 1073, 1977Google Scholar
  154. 154.
    Ziegler JL: Management of Burkitt’s lymphoma: An update. Cancer Treat Rev 6: 95, 1979PubMedCrossRefGoogle Scholar
  155. 155.
    Zwann FE, Hermans J, Berrett M, et al.: Bone marrow transplantation for acute lymphoblastic leukemia. A survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.). Blood 58: 33, 1984Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Dahlia V. Kirkpatrick
  • Lilian Delmonte

There are no affiliations available

Personalised recommendations